Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MediciNova, Inc. (MNOV : NSDQ)

• Company Description    MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and twopreclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $2.40 Daily Weekly Monthly 20 Day Moving Average: 32,338 shares Shares Outstanding: 49.04 (millions) Market Capitalization: $117.70 (millions) Beta: 1.16 52 Week High: $5.09 52 Week Low: $2.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.73% -9.59% 12 Week 2.13% 12.28% Year To Date -10.45% 9.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4275 EXECUTIVE SQUARE SUITE 300 - LA JOLLA,CA 92037 USA ph: 858-373-1500 fax: 858-404-0048 info@medicinova.com http://www.medicinova.com

• General Corporate Information    Officers Yuichi Iwaki - Director; President and Chief Executive Officer Jeff Himawan - Chairman of the Board of Directors Douglas Paulin - Chief Financial Officer Carolyn Beaver - Director Kazuko Matsuda - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 58468P206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 49.04 Most Recent Split Date: (:1) Beta: 1.16 Market Capitalization: $117.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.46 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -100.00% vs. Previous Quarter: -100.00% ROE 03/31/22 - -15.70 12/31/21 - -11.52 09/30/21 - -13.01 ROA 03/31/22 - -14.94 12/31/21 - -10.99 09/30/21 - -12.37 Current Ratio 03/31/22 - 23.13 12/31/21 - 25.42 09/30/21 - 18.13 Quick Ratio 03/31/22 - 23.13 12/31/21 - 25.42 09/30/21 - 18.12 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -34,623.72 12/31/21 - -250.92 09/30/21 - -273.35 Book Value 03/31/22 - 1.64 12/31/21 - 1.71 09/30/21 - 1.77 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©